Correcting Hypocapnia in Aneurysmal Subarachnoid Hemorrhage.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe Chinese University of Hong Kong, Shenzhen
About this trial
Based on the clinical observation that over half of the patients in the management of aneurysmal subarachnoid hemorrhage(aSAH) present with spontaneous hyperventilation, which is significantly associated with delayed cerebral ischemia and poor neurological outcomes, this prospective pilot study is designed to investigate the safety and efficacy of normobaric facemask oxygen for hypocapnia in aSAH.
Eligibility criteria
Qualifiers
Age > 18 years.
Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH), with the presence of an aneurysm verified by computed tomography (CT), CT angiography (CTA), or digital subtraction angiography (DSA).
Hunt-Hess grade II-IV.
Presence of hypocapnia on arterial blood gas analysis, defined as PaCO2 < 35 mmH;
Disqualifiers
Presence of brain herniation or refractory intracranial hypertension, defined as a baseline intracranial pressure (ICP) > 25 mmHg that responds poorly to conventional ICP-lowering therapy;
Primary respiratory diseases (e.g., chronic obstructive pulmonary disease, severe asthma) known to cause chronically elevated baseline PaCO2;
Severe acid-base disturbances other than respiratory alkalosis.
Severe cardiac insufficiency, severe hepatic or renal dysfunction, malignant tumors, or other severe comorbidities that significantly impact prognosis;
Trial design
Treatments tested in this trial
- Normobaric Facemask Oxygen
- control group
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov